

2  
3 **Phytochemical screening and toxicological**  
4 **study of *Neptunia oleracea* Lour. (Mimosaceae)**  
5 **extracts, plant use in traditional medicine**  
6  
7

8  
9  
10  
11 **ABSTRACT**  
12

*Neptunia oleracea* (Lourd.) *Mimosaceae* is a plant commonly used in traditional medicine for the treatment of several pathologies such as dysentery, jaundice, leucorrhoea, troubles of earache, among others.

**Aim:** The purpose of this study was to carry out preliminary phytochemical screening, acute toxicity studies and to evaluate the effect of the aqueous and hydro-ethanolic extracts of *N. oleracea* on intestinal motility *in vivo*.

**Methodology:** Preliminary qualitative phytochemical screening was conducted using standard procedures while acute toxicity studies was performed using OECD method. The effect of *N. oleracea* extracts on intestinal motility was evaluated using on normal and acetylcholine-induced transits.

**Results:** Preliminary qualitative phytochemical screening of aqueous and hydro-ethanolic extracts of *N. oleracea* revealed the presence of similar constituents including steroids, triterpenoids, saponins, tannins, flavonoids, anthocyanidins, coumarins and carbohydrates. Alkaloids was absent in both the extracts. The oral median lethal dose (LD<sub>50</sub>) for both extracts was estimated to be 5000 mg/kg.

The effect of extracts on intestinal peristalsis in mice showed that the aqueous and hydro-ethanolic extracts of *N. oleracea* stimulate normal intestinal transit by 1.29 and 8.54% respectively at the dose of 50 mg/kg body weight, thus there was inhibition at higher doses. These extracts potentiate acetylcholine-induced intestinal transit by 23.9 and 14.39% respectively at 500 mg/kg body weight.

**Conclusion:** The findings of this study showed that the aqueous and hydro-ethanolic extracts of *Neptunia oleracea* contains bioactive constituents that have practically no toxic effect. This could justify the many forms of use of this plant in traditional medicine.

13  
14 *Keywords: Neptunia oleracea; acute toxicity, NMRI mice, Intestinal transit, Burkina Faso*  
15  
16

17 **1. INTRODUCTION**

18 The therapeutic use of medicinal plants is still very present in some countries of the world  
19 and especially in developing countries despite the progress of pharmacology [1]. In Africa,  
20 medicinal plants are valuable resources for the majority of rural populations, where more  
21 than 80% use these plants for health care [2]. In Burkina Faso, traditional medicine and  
22 pharmacopoeia are the main source of primary health care for 70% of the population [3].  
23 *Neptunia oleracea* (*N. oleracea*) is one of the many plants used in traditional medicine in  
24 Burkina Faso to treat different ailments including dysentery, skin diseases, syphilis,  
25 earaches, and guinea worm infections [4].

26 Several authors have expressed interest in the pharmacological and chemical aspect of this  
27 plant. Thus, phytochemical studies have revealed several chemical groups including  
28 flavonoids, anthraquinones and tannins in the aqueous and hydro-ethanolic extracts from *N.*  
29 *oleracea* leaves [5, 6]. Pharmacological studies have shown that *N. oleracea* has astringent,  
30 antimicrobial, anti-tumor and hepatoprotective properties [5, 7, 8].

31 However, there are very few data on the toxicity of this plant. Several studies around the  
32 world have however reported serious side effects related to the use of medicinal plants[9].  
33 Toxic drugs cause serious liver damage and are responsible for about 10% of acute liver  
34 failure and 5% of itching [10, 11]. In Morocco, plant intoxications are responsible for 14.2%  
35 of deaths [12]. In Burkina Faso, more than 22% of renal failure is due to medicinal plants[13].  
36 However, some traditional health practitioners and populations are not always aware of the  
37 toxicity of medicinal plants. Safety and security are therefore important criteria to consider  
38 before administering herbal products. That is why WHO recommends that medicinal plants  
39 should be studied to better understand their therapeutic properties and to ensure their safe  
40 use [14]. The purpose of this work was therefore to carry out the phytochemical profile and  
41 evaluate the toxicity of *N. oleracea* extracts to allow a safety of this medicinal plant.

42

## 43 2. MATERIALS AND METHOD

44

### 45 2.1. Plant material

46 The plant material of *N. oleracea* leaves was harvested in August 2014 in Ouagadougou  
47 (Burkina Faso). It was identified and authenticated at the Burkina Faso National Herbarium  
48 (HNBU) where a voucher specimen was deposited under N°. 8729. The leaves were shade-  
49 dried and pulverized using a laboratory crusher (Blade Crusher, Gladiator East. 1931 Type  
50 BN 1 Mach. 40461 1083). The vegetable powder obtained was used to prepare aqueous  
51 and hydro-ethanolic extracts.

52

### 53 2.2. Experimental animals

54 Toxicological studies were conducted on male and female NMRI mice weighing between 23  
55 and 31 g. The animals were obtained from the "Institut de Recherche en Sciences de la  
56 Santé" (IRSS) pet shop and were reared in controlled room temperature (23-25°C) with 40-  
57 65% of humidity. They were fed with protein enriched wheat cake (29%) and tap water.  
58 These animals were evenly distributed per sex in cages containing three mice each and they  
59 were subjected to 12 hours of illumination and 12 hours of darkness.

60

### 61 2.3. Aqueous decoction preparation

62 A portion (100 g) of the vegetable powder was introduced into a flask containing 700 mL of  
63 distilled water. The mixture was heated under reflux for 1 hour. At the end of this operation,  
64 the decocted extract obtained was filtered using a nylon fabric and then centrifuged at 2000  
65 rpm for 10 minutes. The filtrate obtained was dried in an oven at 45°C under ventilation. The  
66 dried extract obtained was weighed to determine the extraction yield[31].

67

68

69

### 70 2.4. Hydro-ethanolic decoction preparation

71 A sample (100 g) of vegetable powder was placed in a flask containing 500 mL of 80%  
72 hydro-ethanolic solution. The mixture was boiled under reflux for 1 hour. The decoction, after  
73 cooling, was filtered on Whatman N°5 paper and concentrated with rotary evaporator at 60  
74 to 70°C. The concentrated extract was dried in an oven at 45°C under ventilation and  
75 weighed to determine the extraction yield.

76

## 77 **2.5. Phytochemical screening**

78 The aqueous and hydro-ethanolic extracts of *N. oleracea* were subjected to preliminary  
79 phytochemical screening according to the method described by Ciulei [15] and adapted by  
80 the Phytochemistry Laboratory of the Institute for Research in Health Sciences (IRSS).

81

## 82 **2.6. Acute toxicity studies**

83 The acute toxicity study was conducted using the OECD N° 423 guideline [16]. The test was  
84 performed on two groups of three healthy female mice weighing between 23 and 31 g. The  
85 mice were fasted four hours prior to the test.

86 A single dose of 2000 mg/kg body weight (b.w.) of each extract was administered orally  
87 using a gastric tube. After administration of the extracts, the animals were observed every 30  
88 minutes for 2 hours. After the two hours observation, the animals were fed and then  
89 observed daily for 14 days. Mortality and any behavioral change such as changes in skin  
90 and fur, eyes, mucus membranes, convulsion, salivation, diarrhoea, lethargy, sleep and  
91 coma were recorded during the observation period.

92

## 93 **2.7. Effects of *N. oleracea* extracts on intestinal peristalsis *in vivo***

94 The study of the effects of *N. oleracea* aqueous and hydro-ethanolic extracts on intestinal  
95 motility evaluated the effect of these extracts on normal and acetylcholine-induced transit.  
96 This study was carried out according to an adaptation of the protocol described by Tagne *et*  
97 *al.* (2015) [17].

98 The normal transit study was performed using four groups of four mice each. The animals  
99 were fasted for 18 hours before administration of the extracts. The first group (negative  
100 control) received 0.5 mL of 40% activated charcoal in distilled water, orally. The three other  
101 groups were administered with either loperamide at 5 mg/kg, extract at dose of 50 mg/kg  
102 and/or 500 mg/kg b.w., orally[31]. The mice from these three groups received 0.5 mL of 40%  
103 activated charcoal 30 minutes after extracts administration. All the mice were sacrificed 30  
104 minutes after the charcoal administration. The distance travelled by the charcoal in the small  
105 intestine and the whole length of the intestine were measured.

106 Intestinal transit was calculated according to the following formula:

107

$$108 \text{ \% Intestinal transit} = \frac{\text{distance travelled by activated charcoal}}{\text{total length of the small intestine}} * 100$$

109

110 For acetylcholine-induced intestinal transit study, three (3) groups of four mice each per  
111 extract were used. After 18 hours fasting, 0.1 mg/kg of acetylcholine was administered  
112 intraperitoneally (*i.p.*) to the first group (positive control). The two other groups received  
113 acetylcholine at 0.1 mg/kg *i.p.* followed by the extract at 50 and 500 mg/kg b.w. respectively  
114 *per os*.

115 Thirty (30) minutes later, all the mice received 0.5 mL of activated charcoal at 40% in  
116 distilled water. The mice were sacrificed 30 minutes after the activated charcoal

117 administration. The distance travelled by the activated charcoal in the small intestine and the  
118 total length of the small intestine were measured.  
119 Intestinal transit was calculated according to the following formula:

120  
121 
$$\% \text{ Intestinal transit} = \frac{\text{distance travelled by activated charcoal}}{\text{total length of the small intestine}} * 100$$
  
122

## 123 2.8. Statistical analysis

124 Both qualitative and quantitative data were presented in tables. The results of *in vivo* test  
125 were expressed as mean  $\pm$  SD (Standard deviation). The statistical analyses of variance  
126 were done by ONE WAY ANOVA followed by the Dunnett's multiple comparison tests  
127 through the Graph Pad Prism 5.0 program. Differences were considered significant if  $p <$   
128  $0.05$ .  
129

## 130 3. RESULTS

### 131 3.1. Percentage yields

132 After the aqueous and hydro-ethanolic decoctions preparation the extraction yields were  
133 determined. The extraction yields in terms of dry extract ranged from 16.06% to 0.54%  
134 (Table 1).  
135

136 **Table 1:** Percentage yield of *N. oleracea* aqueous and hydro-ethanolic extract

Extracts	Hydro- alcoholic decoction (%)	Aqueous decoction (%)
Crude extraction	15.93 $\pm$ 0 .35	16.06 $\pm$ 1.59

137

### 138 3.2. Preliminary phytochemical screening

139 Preliminary phytochemical screening of *N. oleracea* conducted on the aqueous and hydro-  
140 ethanolic extracts revealed the presence of similar chemical constituents such as flavonoids,  
141 saponins tannins, coumarins, and carbohydrates (Table 2).  
142

143

144 **Table2:** Preliminary phytochemical screening of *N. oleracea* extracts

Chemical compounds	Aqueous decoction	Hydro-ethanolic decoction
Steroids and triterpenoids	+	+
Saponins	+	+
Polyphenolic compounds (tannins)	++	++
Flavonoids	$\pm$	+
Anthocyanidins	+	+
Coumarins	+	+
Alkaloids	-	-
Carbohydrates	+	+

145

**Key:** ++ = abundant; + = scarce;  $\pm$  = trace; - = absent

146 **3.3. Oral acute toxicity study of aqueous and hydro-ethanolic extracts of *N.***  
 147 ***oleracea***

148 The acute toxicity study showed that *N. oleracea* extracts did not cause mortality in NMRI  
 149 mice when administered orally with 2000 mg/kg b.w. No symptoms of intoxication related to  
 150 the extracts was observed during the 72 hours of observation following the administration of  
 151 the extracts and after two weeks of observation (Table 3);

152

153 **Table 3:** Oral acute toxicity study of *N. oleracea* aqueous and hydro-ethanolic extracts  
 154

Extract	First test		Second test	
	Mortality	Mortality rate (%)	Mortality	Mortality rate (%)
Aqueous decoction	0/3	0	0/3	0
Hydro-ethanolic decoction	0/3	0	0/3	0

155

156 In view of the results of this table, the LD<sub>50</sub> of *N. oleracea* extracts was estimated to be 5000  
 157 mg/kg b.w. when administered orally, according to the OECD test guidelines.

158

159 **3.4. Effects of aqueous and hydro-ethanolic extracts from *N. oleracea* on**  
 160 **intestinal transit *in vivo***

161 The effect of aqueous and hydro-ethanolic extracts from *N. oleracea*, on normal intestinal  
 162 transit is presented in Table 5. The results showed that, the extracts (aqueous and hydro-  
 163 ethanolic) at 50 mg/kg b.w. stimulated the normal transit of 1.29 and 8.54 % respectively  
 164 while acetylcholine stimulated the transit of 9.68 % at dose of 0.1 mg/kg b.w. However, at  
 165 500 mg/kg b.w., these extracts inhibited normal transit of 2.59 and 2.07% for aqueous and  
 166 hydro-ethanolic extracts, respectively. Loperamide inhibited this transit of 20.18% at 5 mg/kg  
 167 b.w.; the normal intestinal transit was 64.17 ± 8.05[31].

168

169 **Table 4:** Effect of *N. oleracea* extracts on normal intestinal transit  
 170

Treatment	Dose (mg/kg)	Intestinal transit	Inhibition rate (%)	Stimulation rate (%)
Normal control		64.17 ± 8.05		
Acetylcholine	0.1	73.84 ± 4.63		9.68
Loperamide	5	43.98 ± 4.81	20.18	
Aqueous extract	50	65.45 ± 12.98		1.29
	500	61.57 ± 8.79	2.59	
Hydro-ethanolic extract	50	72.71 ± 3.10		8.54
	500	62.09 ± 1.77	2.07	

171

172 Table 5 presents the results of acetylcholine-induced intestinal transit test. The results  
 173 indicated that the aqueous and hydro-ethanolic extracts from *N. oleracea* potentiated the  
 174 intestinal transit induced by acetylcholine. At a dose of 50 mg/kg, aqueous and hydro-  
 175 ethanolic extracts from *N. oleracea* increased acetylcholine-induced intestinal transit of  
 176 10.85 and 7.04% respectively. At 500 mg/kg body weight, the aqueous extract increased

177 acetylcholine-induced intestinal transit of 23.90%. At the same dose, hydro-ethanolic extract  
178 stimulated acetylcholine-induced intestinal transit of 14.39%.

179  
180  
181  
182

**Table 5:** Effect of aqueous and hydro-ethanolic extracts from *N. oleracea* on acetylcholine-induced intestinal transit

Treatment	Dose (mg/kg)	Intestinal transit	Stimulation rate (%)
Normal control		64.17 ± 8.05	
Acetylcholine	0.1	73.84 ± 4.63	9.68
Aqueous extract	50	75.02 ± 4.09	10.85
	500	88.07 ± 7.65	23.90
Hydro-ethanolic extract	50	71.21 ± 3.48	7.034
	500	78.56 ± 3.45	14.39

183  
184

#### 4. DISCUSSION

185 Plants produce a variety of natural substances including secondary metabolites to protect  
186 against predators and pathogens. These secondary metabolites are most often responsible  
187 for the toxicity of certain plants [18]. According to some authors, 20% of plants were once  
188 used as abortive, 20% for criminal purposes, 15% for witchcraft and 10% for psychoactive  
189 plants [19]. Among the toxic secondary metabolites of plants are coumarins, which have  
190 spasmolytic properties. Some of them (hydroxycoumarins) cause haemorrhagic diarrhea,  
191 haematuria and dyspnea, which can lead to death. Toxic diterpenoids induce violent  
192 digestive disorders or severe skin or eye irritations. Tannins cause reduced growth in  
193 animals by inhibiting the metabolic use of amino acids after absorption [20].

194 Phytochemical screening of aqueous and hydro-ethanolic extracts of *N. oleracea* leaves  
195 revealed the presence of several chemical constituents including steroids, flavonoids,  
196 tannins, saponins, etc. These results are in consistent to what was reported by other authors  
197 for the different parts of this plant [5, 21, 22].

198 In the oral acute toxicity study, the estimated LD50 was 5000 mg/kg for the aqueous and  
199 hydro-ethanolic extracts from *N. oleracea*. These extracts can be classified in category 5, ie  
200 substances unlikely to present acute hazard according to the Globally Harmonized System  
201 of Classification and Labeling of Chemicals of the United Nations [23]

202 The results is in agreement with those of previous studies which has noted the absence of  
203 mortality up to dose of 2000 mg / kg aqueous and hydro-ethanolic extracts of *N. oleraceae* in  
204 single oral administration [5, 7]. This low toxicity could support the multiple uses of this plant  
205 in traditional medicine.

206 However, since this study focused on acute toxicity, repeated-dose toxicity studies will  
207 provide a better understanding of the toxic potential of these extracts.

208 The results of the intestinal transit study showed that acetylcholine stimulated intestinal  
209 transit. The aqueous and hydro-ethanolic extracts of *N. oleracea* stimulated normal intestinal  
210 transit at low dose while at high doses both extracts inhibited normal transit. Also these  
211 extracts stimulated acetylcholine-induced intestinal transit.

212 The gastrointestinal peristalsis is controlled by the cholinergic system, of which  
213 acetylcholine is one of the neurotransmitters [24]. It is synthesized by enteric excitatory motor  
214 neurons and its binding to the M3 receptor of the gastrointestinal tract leads to an increase  
215 of motility, tone and intestinal peristalsis [25]. Acetylcholine has ability to activate parietal  
216 cells and G cells as well as enterochromaffin cells (ECL). G cells and ECL cells produce

217 gastrin and histamine respectively. Gastrin, histamine and acetylcholine are hormones that  
218 promote digestion by stimulating the secretion of protons. In addition, acetylcholine and  
219 cholinergic agonists by activating muscarinic M3 and M1 receptors inhibit the absorption of  
220 sodium and chloride ions and stimulate the secretion of these ions and water into the colon  
221 [26].

222 Apart from acetylcholine, vasoactive intestinal peptide (VIP), nitric oxide (NO) and ATP are  
223 neurotransmitters synthesized by inhibitory neurons whose release induces muscle  
224 relaxation of the gastrointestinal tract [27]. The aqueous and hydroethanolic extracts of *N.*  
225 *oleracea* is believed to act as an acetylcholine agonist on M3 muscarinic receptors, G cells  
226 or ECL cells in the gastrointestinal tract, increasing the tone and contractions of the intestine,  
227 resulting in increased intestinal transit. This mechanism may also explain the exacerbation of  
228 the effect of acetylcholine on intestinal transit. The inhibition of normal intestinal transit by  
229 aqueous and hydro-ethanolic extracts from *N. oleracea* at high-dose would be related to the  
230 capacity of metabolites present in these extracts to occupy other receptors whose activation  
231 would cause adverse effects of acetylcholine such as opioid receptors ( $\mu$ ). Indeed, the  
232 activation of muscular opioid receptors ( $\mu$ ) in the gastrointestinal tract reduces motility and  
233 propulsive contractions and gastric emptying, but leads to an increase in muscle tone and  
234 non-propulsive (segmental) contractions [28]. It is also possible that these extracts, in high  
235 doses, inhibit intestinal motility by acting directly on circular muscles and long intestinal  
236 muscles such as loperamide [29]. The traditional use of *N. oleracea* could cause diarrhea to  
237 the patient due to the ability to exacerbate the effect of acetylcholine, or constipation if given  
238 at high doses.

239 According to [30], coumarins, anthraquinones and alkaloids are believed to have purgative  
240 properties . However, phytochemical analysis revealed the presence of coumarins and  
241 phenolic compounds in aqueous and hydroethanolic extracts from *N. oleracea*. The  
242 presence of these compounds could justify the effect of *N. oleracea* extracts on  
243 gastrointestinal transit.

244

## 245 **5. CONCLUSION**

246 This study indicated the presence of different chemical constituents in aqueous and hydro-  
247 ethanolic decoctions from *N. oleracea* leaves; and the acute oral toxicity study of the  
248 aqueous and hydro-ethanolic extracts from *N. oleracea* was found to be safe orally. The  
249 extracts stimulated basic bowel contractions at low dose but induced inhibition of these  
250 contractions at high dose. In view of these results, it can be concluded that the many forms  
251 of use of this plant in traditional medicine can be justified by its richness in secondary  
252 metabolites and its low toxicity.

253

254

255

## 256 **CONSENT**

257 Not applicable.

258

## 259 **ETHICAL APPROVAL**

260 The experimental protocol was carried out in accordance with international standard  
261 protocols [Guidelines set by the European Union on the protection of animals (CEC Council  
262 86/609)] and adopted by IRSS, Burkina Faso. These different experiments were carried out  
263 on the mice and did not concern in any case the human subject. These protocols are ethical  
264 to experiment on laboratory animals.

265

266

267

## REFERENCES

268

1. Tabuti JRS, Lye KA, Dhillion SS. Traditional herbal drugs of Bulamogi, Uganda: Plants, use and administration. *J Ethnopharmacol.* 2003;88:19–44.

269

2. OMS B régional de L. Traditional medicine in Cambodia part one. 2011.

270

271

3. Zerbo P, Millogo-Rasolodimby J, Nacoulma-Ouedraogo OG, Van Damme P. Plantes médicinales et pratiques médicales au Burkina Faso : cas des Sanan. *Bois Forêts des Trop.* 2011;65:41–53.

272

273

274

4. Heang, Al. P et. Traditional medicine in Cambodia part one. 2013.

275

276

5. Bhoomannavar VS, Patil VP, Hugar S, Nanjappaiah HM, Kalyane N. Anti-ulcer activity of *Neptunia oleracea* Lour. *Pharmacologyonline.* 2011;3 January 2011:1015–20.

277

278

279

6. Lee SY, Mediani A, Ismail IS, Maulidiani, Abas F. Antioxidants and  $\alpha$ -glucosidase inhibitors from *Neptunia oleracea* fractions using 1 H NMR-based metabolomics approach and UHPLC-MS/MS analysis 03 Chemical Sciences 0301 Analytical Chemistry. *BMC Complement Altern Med.* 2019;19:1–15.

280

281

282

7. Bhoomannavar VS, Shivakumar SI, Hallikeri CS, Hatapakki BC. Hepatoprotective activity of leaves of *Neptunia oleracea* lour in carbon tetrachloride induced rats. *Res J Pharm Biol Chem Sci.* 2011;2:309–14.

283

284

285

8. Nakamura Y, Murakami A, Koshimizu K, Ohigashi H. Identification of Pheophorbide a and Its Related Compounds as Possible Anti-tumor Promoters in the Leaves of *Neptunia oleracea*. *Biosci Biotechnol Biochem.* 1996;60:1028–30.

286

287

288

9. Kande B, Yao K, Allah-Kouadio E, Kone MW. Enquête sur l'utilisation et l'effet des médicaments à base de plantes chez les patients hépatiques hospitalisés au Service de médecine et d'hépatogastroentérologie du Centre Hospitalier Universitaire (CHU) de Cocody en Côte d'Ivoire. *J Appl Biosci.* 2018;130:13220.

289

290

291

10. Døssing M, Sonne J. Drug-Induced Hepatic Disorders: Incidence, Management and Avoidance. *Drug Saf.* 1993;9:441–9.

292

293

294

11. Thompson M, Jaiswal Y, Wang I, Williams L. Hepatotoxicity: Treatment, causes and applications of medicinal plants as therapeutic agents. *J Phytopharm.* 2017;6:186–93.

295

296

297

12. Yassir B et al. No Title. 2012.

298

299

14. Subha1 D, Geetha N. Evaluation of acute toxicity of the methanolic extract of *Tanacetum parthenium* L. in albino wistar rats. *J Sci Innov Res.* 2017;6:113–5. [www.jsirjournal.com](http://www.jsirjournal.com).

300

301

15. Ciulei. Practical Manuals on the Industrial Utilization of Medicinal and Aromatic Plants. Methodology for Analysis of Vegetable Drugs. 1st Edn. Bucarest; 1982.

302

303

304

16. OECD. OECD/OCDE 423 OECD GUIDELINE FOR TESTING OF CHEMICALS Acute Oral Toxicity-Acute Toxic Class Method. 2001. [https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecd\\_gl423.pdf](https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecd_gl423.pdf). Accessed 10 Aug 2019.

305

306

307

17. Archange M, Tagne F, Kamgang R, Noubissi PA, Oyono J-LE. Activity of *Oxalis barrelieri* aqueous extract on rat secretory diarrhea and intestine transit ARTICLE INFO ABSTRACT. *J Appl Pharm Sci.* 2015;5:58–062. doi:10.7324/JAPS.2015.50111.

308

309

310

18. Schäfer H, Wink M. Medicinally important secondary metabolites in recombinant microorganisms or plants: Progress in alkaloid biosynthesis. *Biotechnol J.* 2009;4:1684–703.

311

312

313

19. Imane Z, Jihane I, Amal A, Souad S, Yassir B. Evaluation of the therapeutic and toxicological knowledge of herbalists on the most notified plants in the poison control and pharmacovigilance center of Morocco. *J Pharmacogn Phyther.* 2018;10:126–32.

314

315

316

20. Mole S, Butler LG, Iason G. Defense against dietary tannin in herbivores: A survey for proline rich salivary proteins in mammals. *Biochem Syst Ecol.* 1990;18:287–93. doi:10.1016/0305-1978(90)90073-O.

317



- 318 21. Nafuka SN, Mumbengegwi DR. Phytochemical Analysis and In Vitro Anti-plasmodial  
319 Activity of Selected Ethnomedicinal Plants Used to Treat Malaria Associated Symptoms in  
320 Northern Namibia. 2013.
- 321 22. Soulama S, Sanon H, Meda R, Boussim J. Teneurs en tanins de 15 ligneux fourragers  
322 du Burkina Faso. *Afrique Sci Rev Int des Sci Technol.* 2014;10:180–90.  
323 <https://www.ajol.info/index.php/afsci/article/view/118347>. Accessed 10 Aug 2019.
- 324 23. United Nations. GLOBALLY HARMONIZED SYSTEM OF CLASSIFICATION AND  
325 LABELLING OF CHEMICALS (GHS). ST/SG/AC.1. 2017.  
326 [https://www.unece.org/fileadmin/DAM/trans/danger/publi/ghs/ghs\\_rev07/English/ST\\_SG\\_AC](https://www.unece.org/fileadmin/DAM/trans/danger/publi/ghs/ghs_rev07/English/ST_SG_AC)  
327 [10\\_30\\_Rev7e.pdf](https://www.unece.org/fileadmin/DAM/trans/danger/publi/ghs/ghs_rev07/English/ST_SG_AC). Accessed 10 Aug 2019.
- 328 24. Roberts RR, Murphy JF, Young HM, Bornstein JC. Development of colonic motility in the  
329 neonatal mouse-studies using spatiotemporal maps. *Am J Physiol - Gastrointest Liver*  
330 *Physiol.* 2007;292:5–7.
- 331 25. Briet J, Javelot H, Vaillau JL. Échelle D'Imprégnation Anticholinergique : Mise Au Point  
332 D'Une Nouvelle Échelle Incluant Les Molécules Françaises, Et Application En Psychiatrie.  
333 *Eur Psychiatry.* 2015;30:S154–5.
- 334 26. Zimmerman TW, Dobbins JW, Binder HJ. Mechanism of cholinergic regulation of  
335 electrolyte transport in rat colon in vitro. *Am J Physiol - Gastrointest Liver Physiol.* 1982;5.
- 336 27. Furness JB. The enteric nervous system and neurogastroenterology. *Nat Rev*  
337 *Gastroenterol Hepatol.* 2012;9:286–94.
- 338 28. Holzer P. Opioid receptors in the gastrointestinal tract. *Regulatory Peptides.*  
339 2009;155:11–7.
- 340 29. Wilcock SCA, Twycross R, Regnard C, Twycross R, Mihalyo M. *Therapeutic Reviews.*  
341 2011;42:319–23.
- 342 30. Mamyrbekova-bekro JA, Boua BB, Bekro Y. Biological guided phytochemical screening  
343 and in vitro evaluation of the purgative properties of *Anchomanes difformis* (Blume) Engl., A  
344 plant used in Ivory Coast in the folk treatment of constipation. 2013: 20-6.
- 345 31. Atawodi, S. E., Olowoniyi, O. D., Adejo, G. O., Liman, M. L., & Dubey, N. K. (2014).  
346 Review of the antioxidant potential of African medicinal and food plants. *Plants as a Source*  
347 *of Natural Antioxidants*, 34.
- 348